Featured Article
Precision Oncology Today
Magazine
MRD: The Future Foundation of Solid Tumor Trials
The terms minimal residual disease, measurable residual disease, and molecular residual disease, interchangeably referred to as MRD, denote what is left after cancer treatment with curative intent. Originally used to monitor patients with hematologic malignancies, MRD is becoming increasingly important in the field of solid tumor oncology because of its correlation with disease outcomes.
Relatively Speaking: Unexpected Detours, Can Inconclusive Prenatal Genetic Tests Save Lives?
By Blair Stevens
Uncertain genetic testing results are not an unusual event in the field of genetic counseling. Obstetricians routinely refer patients to genetic counselors...
Trending on Inside Precision Medicine
Wyss Institute, Northpond Labs to Develop Cell Therapy Delivery Tech
The research is focused on finding effective methods for getting therapeutic cells to their targets in the body so they can interact with diseased cells.
Polygenic Risk Scores Help Predict Type 2 Diabetes Risk in South Asians
Queen Mary University of London researchers evaluated whether genetic variants linked to type 2 diabetes in Europeans are also relevant in British Pakistani and Bangladeshi people.
Belief BioMed’s Hemophilia Gene Therapy Passes Phase I
Belief BioMed’s gene therapy showed very promising results in a Phase I study for hemophilia. This was the first-of-its-kind study in Asia.
